MAPK/ERK pathway
From Proteopedia
(Difference between revisions)
Line 33: | Line 33: | ||
===MAPKs=== | ===MAPKs=== | ||
- | *[[Mitogen-activated protein kinase]] | ||
*[[Mitogen-activated protein kinase kinase]] | *[[Mitogen-activated protein kinase kinase]] | ||
+ | *[[Mitogen-activated protein kinase]] | ||
*[[Michael Roberts/BIOL115/ERK2]] | *[[Michael Roberts/BIOL115/ERK2]] | ||
*[[UMass Chem 423 Student Projects 2011-2#p38 kinase|p38 MAPK (UMass Chem 423 Student Projects 2011-2)]] | *[[UMass Chem 423 Student Projects 2011-2#p38 kinase|p38 MAPK (UMass Chem 423 Student Projects 2011-2)]] |
Revision as of 13:46, 17 February 2022
|
References
- ↑ Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR, Weber BL. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002 Dec 1;62(23):6997-7000. PMID:12460918
- ↑ Antony R, Emery CM, Sawyer AM, Garraway LA. C-RAF mutations confer resistance to RAF inhibitors. Cancer Res. 2013 Aug 1;73(15):4840-51. doi: 10.1158/0008-5472.CAN-12-4089. Epub, 2013 Jun 4. PMID:23737487 doi:http://dx.doi.org/10.1158/0008-5472.CAN-12-4089